{
    "clinical_study": {
        "@rank": "79042", 
        "arm_group": [
            {
                "arm_group_label": "Transdermal Electroacupuncture - Arm A", 
                "arm_group_type": "Experimental", 
                "description": "week 1-2 real treatment, week 3-6 sham treatment  with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed"
            }, 
            {
                "arm_group_label": "Transdermal Electroacupuncture - Arm B", 
                "arm_group_type": "Experimental", 
                "description": "week 1-2 real treatment, week 3-6 sham treatment  with Han's Acupoint Nerve Stimulator  treatment while receiving concurrent buprenorphine-naloxone as prescribed"
            }
        ], 
        "brief_summary": {
            "textblock": "Pilot study of 12 outpatients in early recovery from illicit drug use,post-detox and  on\n      buprenorphine-naloxone maintenance will be offered 12 TEAS adjunct treatments over 6\n      weeks(X2/week) to ascertain if they experience  any improvement in mood,sleep,overall\n      quality of life and decrease drug cravings ultimately while facing everyday life stressors."
        }, 
        "brief_title": "Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Opioid-use Disorder", 
        "detailed_description": {
            "textblock": "-  this crossover study will involve participants who will be randomized into two\n           treatment groups,A&B. TEAS treatments will be given for 30 minutes,X2/week,for 6\n           weeks(12total sessions). Group A will receive 2 weeks(4 sessions) of active treatment\n           followed by 4 weeks of sham treatment(8 sessions). Group B will receive 2 weeks(4\n           sessions) of sham treatment,2 weeks (4 sessions)of real treatment,and finally 2 weeks\n           (4 sessions) of sham treatment.\n\n        -  parameters to be measured include vital signs and questionnaires weeks 1,3,5,6 to\n           assess self-reported past 14-day substance use,alcohol and drug craving,withdrawal\n           symptoms,sleep,mood,pain and overall quality of life.\n\n        -  goals include better lives for post-detox opiate addicts as they incorporate this\n           treatment into their lives,saving themselves and loved ones more horror,and their\n           communities resources."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18-59 years old\n\n          -  early recovery(0-3months of abstinence\n\n          -  not currently detoxing\n\n          -  maintained on buprenorphine-naloxone under the care of qualified MD\n\n          -  proficient in the English language\n\n          -  abstinent from other illicit drug use disorders or co-occuring alcohol dependence\n\n        Exclusion Criteria:\n\n          -  history of prior acupuncture treatment\n\n          -  having acute,psychiatric symptoms which would pose safety concerns,or an adherence to\n             treatment barrier(active suicidality/psychosis/mania)\n\n          -  cognitive disorders*not competent to give informed consent\n\n          -  active cardiac disease or EKG abnormalities or with cardiac pacemaker\n\n          -  currently detoxing from alcohol or illicit drugs\n\n          -  inability or  non-intention to attend all treatment sessions*history of\n             seizures*pregnancy or breast feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033746", 
            "org_study_id": "2013P001595"
        }, 
        "intervention": {
            "arm_group_label": [
                "Transdermal Electroacupuncture - Arm A", 
                "Transdermal Electroacupuncture - Arm B"
            ], 
            "description": "frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).", 
            "intervention_name": "Han's Acupoint Nerve Stimulator", 
            "intervention_type": "Device"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Belmont", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02478"
                }, 
                "name": "McLean Hospital"
            }, 
            "investigator": {
                "last_name": "Barbara A MacIntyre, MSN, RN", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Crossover Study Using Transdermal Electroacupuncture as Adjunctive Treatment to Reduce Opiate Cravings in Post-Detox Outpatients Receiving Buprenorphine-Naloxone", 
        "overall_contact": {
            "email": "bmacintyre@partners.org", 
            "last_name": "Barbara A MacIntyre, MSN, RN", 
            "phone": "617-855-2771"
        }, 
        "overall_official": {
            "affiliation": "Mclean Hospital", 
            "last_name": "Barbara A MacIntyre, MSN,RN", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants who attend all 12 Transdermal Electroacupuncture (TEAS) sessions", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033746"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mclean Hospital", 
            "investigator_full_name": "Barbara MacIntyre MSN,RN", 
            "investigator_title": "Barbara MacIntyre MSN,RN", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Mood measured by self-report on the Quick Inventory of Depressive Symptomatology (QIDS-SR-16) questionnaire.", 
                "measure": "Number of participants who experience improvement in mood", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Sleep patterns measure by self report through the Pittsburgh Sleep Quality Index (PSQI) questionnaire", 
                "measure": "Number of participants who experience improvement in sleep", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Quality-of-Life measured by self-report through Short Form (SF)-36 questionnaire", 
                "measure": "Number of participants who experience improvement in Quality-of-Life", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Cravings for drugs and alcohol measure by self-report through the Brief Addiction Monitor (BAM), the Craving Scale (CS), the Subjective Opiate Withdrawal Scale (SOWS), Substance Use Report, and a Brief Pain Inventory", 
                "measure": "Number of participants who report fewer cravings for drugs and alcohol", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Mclean Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mclean Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}